Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14.

Roland B Walter^{1

2

3}, Megan Othus⁴, Kaysey F Orlowski⁵, Emily N McDaniel⁵, Bart L Scott^{5

6}, Pamela S Becker^{5

2}, Mary-Elizabeth M Percival^{5

2}, Paul C Hendrie², Bruno C Medeiros⁷, Michael T Chiarella⁸, Arthur C Louie⁸, Elihu H Estey^{5

2}

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA rwalter@fredhutch.org.
² Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
³ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁴ Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁵ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁶ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
⁷ Stanford University, CA, USA.
⁸ Jazz Pharmaceuticals, Ewing, NJ, USA.

No abstract available

Publication types